Johnson & Johnson Agrees to Buy Ollin Biosciences for $2.2 Billion
Johnson & Johnson announced a $2.2 billion deal for Ollin Biosciences, adding an investigational eye-disease drug to its pipeline.
Johnson & Johnson has agreed to acquire clinical-stage biotechnology company Ollin Biosciences for $2.2 billion upfront, in a deal that would expand the healthcare company’s ophthalmology pipeline.
Deal adds an experimental eye-disease treatment
J&J said the acquisition would bring OLN324 into its portfolio. The investigational bispecific antibody is being developed for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema. The company described OLN324 as a Phase 3 candidate; it remains an investigational medicine and is not an approved treatment.
Additional payments could follow
The proposed transaction includes the $2.2 billion upfront payment and the possibility of up to approximately $1.125 billion in additional regulatory and commercial milestone payments. J&J said the deal is expected to close before the end of 2026, subject to regulatory approvals and customary closing conditions.
Separately, Blackstone Life Sciences is expected to provide $750 million over multiple years to fund Phase 3 development. The funding arrangement includes potential milestone payments and royalties for Blackstone.
Why investors may watch the deal
The acquisition reflects continued investment by large pharmaceutical companies in specialist medicines and treatments for serious eye conditions. Its eventual value will depend on clinical results, regulatory decisions, commercial adoption and whether the transaction closes as planned.
J&J cautioned that development and regulatory outcomes are uncertain. OLN324’s potential benefits have not yet been established through completed approval and commercial use.
Source
This report is based on the linked primary announcement or official data release. The newsroom has summarized the source and identified its claims; it does not claim independent eyewitness reporting.
Editorial note: This article is for news and information, not investment or medical advice. Contact the newsroom to report a correction.